BMY

Bristol Myers Squibb
Pharmaceuticals · Health Care · as of 2026-11-20
Last close
$59.14
+1.4% on the session
1-year return
+35.0%
+1.6% over six months
Volatility
27.8%
annualized, trailing year
Max drawdown
-15.9%
worst peak to trough, 1y
What the numbers say

Bristol Myers Squibb is a pharmaceuticals name in the health care sector. Over the past year it returned +35.0%, against -11.2% over three months and -6.1% over one. It sits 0.6% below its 200-day average, close enough that the trend is undecided. Annualized volatility of 27.8% is moderate by single-stock standards.

Its worst peak-to-trough decline over the year was -15.9%, and it has traded a median $629M a day, the figure that decides whether a position can actually be entered and exited at posted prices. Its daily moves correlate 0.13 with the S&P 500 proxy, so it has been moving substantially on its own.

Where it ranks
Within Health Care#45 of 59
Stronger than 24% of its sector on the momentum profile
Across the whole index#237 of 497

How BMY scores on all four profiles

Its standing on steadiness, defensiveness and rebound, plus the factor-by-factor breakdown behind each score, and its closest and least-correlated peers among 6 others in Pharmaceuticals.

Start a free 7-day trial
Full metrics
1 day+1.4%
1 week-6.8%
1 month-6.1%
3 months-11.2%
6 months+1.6%
1 year+35.0%
12-1 momentum+43.8%
Volatility (1y, annualized)27.8%
Max drawdown (1y)-15.9%
Distance vs 200-day average-0.6%
Return per unit of risk1.26
Median daily dollar volume$629M
Free newsletter

Get BMY when it shows up in a ranking

Two editions a weekday, free, ranked lists built from this same data, on whatever the market is talking about.

Everything on this page is computed from daily adjusted closing prices. It contains no earnings, balance-sheet, guidance or ownership data, and it is not a valuation. Nothing here is tailored to your circumstances or a recommendation to buy or sell. Past performance does not predict future results.